Glatiramer acetate

(Copaxone®)

Glatiramer acetate

Latest News

loading GIF

Drug updated on 4/17/2024

Dosage FormInjection (subcutaneous; 20 mg/mL, 40 mg/mL)
Drug ClassAcetate salts of synthetic polypeptides
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Glatiramer acetate (Copaxone) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
  • Three systematic reviews/meta-analyses were analyzed to compare Copaxone's effectiveness and safety profile with other disease-modifying treatments (DMTs) for managing MS.
  • While not top-ranked for preventing relapse recurrence or disability worsening during the first 24 months of treatment compared to drugs like alemtuzumab, mitoxantrone, natalizumab, and fingolimod; Copaxone has demonstrated potential in mitigating MS-associated cognitive decline.
  • The drug also shows promise as a neuroprotective agent particularly in neurological conditions with cognitive decline aspects such as Alzheimer's Disease, indicating its broad therapeutic implications beyond just relapse prevention.
  • A meta-analysis covering 44 studies revealed that DMTs, including Copaxone, had a small to moderate positive effect on cognitive test performance in RRMS patients, suggesting it is as effective as other DMTs at addressing this critical aspect of MS.
  • Although specific population types or subgroup considerations are not deeply explored within these studies; they suggest potential benefits across diverse patient demographics due to emphasis on improving cognition and providing neuroprotection.